Post Hoc Analysis
CPS
The ORRs were 76.7% for patients with dose reduction and/or permanent discontinuation (n = 30) and 53.6% for patients with sustained medication without reduction (dose pause permitted, n = 28); however, the difference of ORR between the two subgroups was not significant (Using CPS ≥ 10 as a cutoff, no difference in ORR between the PD-L1–positive patients (n = 32) and PD-L1–negative ones (n = 15) was observed (65.6% TMB information was available for 23 patients (39.7%), and they were classified into the low- and high-TMB subgroups using the median TMB value (1.26 muts/Mb). No significant differences in ORR, PFS, or DoR were observed between the two groups (Data Supplement).